# Comprehensive Faculty Q&A Bank: Decompensated Chronic Liver Disease ### Compiled from Previous Case Presentation Sessions — Postgraduate Internal Medicine --- ## FROM RABIN MAHARJAN'S CASE (46F, Ascites + Bilateral Leg Swelling + SOB) --- **Q1. If ascites is the first presentation → bad prognosis. If UGI bleed → better prognosis. Explain this paradox.** **Answer:** This is a well-established clinical observation rooted in the natural history of cirrhosis and the BAVENO consensus. **Ascites as first decompensation → worse prognosis:** Ascites signifies severe portal hypertension (HVPG ≥12 mmHg) combined with profound hepatic synthetic failure (low albumin → reduced oncotic pressure) and neurohormonal activation (RAAS, SNS, ADH). The 1-year mortality after first ascites is **20–40%** and 5-year mortality is **50%** (EASL CPG 2018). Ascites also predicts future complications — SBP (25–30%/year), HRS (18%/year), and HE — creating a downward spiral. **Variceal bleed as first decompensation → relatively better prognosis:** Variceal bleeding can occur even at a relatively preserved hepatic synthetic function (Child A/B), triggered by a threshold HVPG ≥12 mmHg alone, without necessarily requiring the degree of hepatocellular dysfunction that ascites demands. A Child A patient bleeding from varices has a 6-week mortality of ~5–10%, whereas a Child C patient with ascites has far higher short-term mortality. The **CANONIC study (Moreau et al., *Hepatology* 2013)** showed that among decompensation events, ascites alone conferred the worst median transplant-free survival. > **Reference:** EASL CPG Decompensated Cirrhosis, *J Hepatol* 2018; D'Amico G et al., *J Hepatol* 2014. --- **Q2. Add history of malnutrition — why is this important?** **Answer:** Malnutrition is present in **50–90% of cirrhotics** and is an independent predictor of mortality, complications (infections, HE, poor wound healing), and post-transplant outcomes. **Pathophysiology in cirrhosis:** - Reduced glycogen stores → accelerated starvation (overnight fast equivalent to 3-day fast in healthy person). - Protein catabolism: reduced branched-chain amino acids (BCAA), elevated aromatic amino acids (Fischer ratio) → HE risk. - Zinc deficiency → impaired urea cycle → hyperammonaemia. - Fat malabsorption → deficiency of fat-soluble vitamins (A, D, E, K). - Sarcopenia (reduced skeletal muscle mass) → independently predicts 6-month mortality (Montano-Loza et al., *Hepatology* 2012). **How to assess:** - **Royal Free Hospital Global Assessment (RFH-GA):** Validated for cirrhosis; includes BMI, mid-arm circumference, dietary intake. - **Handgrip strength** (dynamometry): Sarcopenia marker; <30 kg (men) = significant. - **DEXA scan / CT L3 skeletal muscle index:** Research tool for sarcopenia quantification. **Management:** - Caloric target: 35–40 kcal/kg/day; protein: 1.2–1.5 g/kg/day (protein restriction is OBSOLETE in cirrhosis). - Late evening snack (LES): 50g complex carbohydrate at bedtime — reduces overnight fasting catabolism. - BCAA supplementation if protein-intolerant. > **Reference:** ESPEN Guidelines on Liver Disease, *Clinical Nutrition* 2019; Montano-Loza AJ et al., *Hepatology* 2012. --- **Q3. Budd-Chiari Syndrome (BCS) as a presentation — what is it, and what causes it? What is HVOTO?** **Answer:** **Budd-Chiari Syndrome** is defined as hepatic venous outflow tract obstruction (HVOTO) at any level from the small hepatic venules to the right atrium, excluding cardiac causes (e.g., constrictive pericarditis, right heart failure). **Classification:** - Primary BCS: Thrombosis of hepatic veins / IVC due to underlying thrombophilia. - Secondary BCS: Tumour invasion (HCC, renal cell carcinoma), web/membrane. **Causes (mnemonic: MPN-HAP):** - Myeloproliferative Neoplasms (JAK2 V617F mutation) — most common (40–50%); polycythaemia vera is the single largest cause. - Paroxysmal Nocturnal Haemoglobinuria (PNH). - Antiphospholipid Syndrome. - Inherited thrombophilias: Factor V Leiden, Prothrombin G20210A, Protein C/S/ATIII deficiency. - Pregnancy/OCP use. - Behçet's disease (IVC involvement particularly). - Abdominal malignancy (extrinsic compression/invasion). **Clinical triad:** Abdominal pain + hepatomegaly + ascites (massive, exudative, high protein). Unlike cirrhotic ascites (which is transudative), BCS ascites has SAAG ≥1.1 g/dL but protein >2.5 g/dL. **Diagnosis:** Triphasic CT / MRI — shows caudate lobe hypertrophy (independent venous drainage via accessory hepatic veins to IVC), absent/thrombosed hepatic veins, "flip-flop" enhancement pattern. Doppler USG: absent hepatic vein flow, spider-web pattern. **HVOTO = Hepatic Venous Outflow Tract Obstruction** — the pathophysiological umbrella term encompassing BCS at any level. > **Reference:** EASL CPG Vascular Diseases of the Liver, *J Hepatol* 2016; DeLeve LD et al., *Hepatology* 2009. --- **Q4. How do you take BMI in an oedematous/ascitic patient?** **Answer:** Standard BMI (weight/height²) is **unreliable** in oedematous or ascitic patients because measured weight includes fluid weight (ascites + peripheral oedema), overestimating true lean body mass. **Approaches:** 1. **Estimated dry weight:** Subtract estimated fluid weight. Clinically estimate ascites volume (mild ~1–2L, moderate ~4–6L, tense ~8–12L) and oedema weight (~1–2L per grade of bilateral pitting oedema). - `Dry weight = Actual weight − Ascites weight − Oedema weight` 2. **Mid-arm circumference (MAC) and mid-arm muscle circumference (MAMC):** Not affected by fluid distribution. MAMC = MAC − (π × triceps skinfold thickness). Better nutritional marker. 3. **Handgrip strength (HGS):** Dynamometry — functional measure of muscle mass. Validated surrogate for sarcopenia in cirrhosis. 4. **Post-paracentesis weight:** Weigh the patient after large-volume paracentesis for closer approximation. 5. **Bioelectrical Impedance Analysis (BIA):** Can estimate lean body mass, but accuracy is limited in significant ascites. **Practical point:** ESPEN 2019 recommends using **subjective global assessment (SGA) or RFH-GA** rather than BMI alone for nutritional assessment in cirrhosis. > **Reference:** ESPEN Guidelines on Liver Disease, *Clinical Nutrition* 2019. --- **Q5. What is the minimum amount and duration of alcohol required to develop CLD?** **Answer:** This is a critical question with a nuanced, gender-differentiated answer. **Threshold quantities (EASL ALD Guidelines 2018, updated 2023):** | Parameter | Men | Women | |---|---|---| | Minimum "significant" intake | >21 units/week (210g/week) | >14 units/week (140g/week) | | Threshold for ALD risk | >30g/day for >5 years | >20g/day for >5 years | | High-risk for cirrhosis | >60–80g/day for >10 years | >20–40g/day for >10 years | **1 unit = 8–10g of pure alcohol** (UK definition); 1 standard drink (USA) = 14g. **Key concepts:** - Women develop ALD at **lower doses and shorter durations** — due to lower gastric ADH activity, higher body fat percentage (less volume of distribution for ethanol), and oestrogen-mediated enhanced hepatotoxicity. - Only **~10–15% of heavy drinkers** develop cirrhosis → genetic susceptibility (PNPLA3 I148M polymorphism most studied), nutritional status, obesity, and viral co-infection are major modifiers. - **Pattern of drinking** matters: binge drinking (>60g in a session) is more hepatotoxic than equivalent daily intake. - **Total lifetime dose** (grams of alcohol × years) correlates best with fibrosis progression. **This patient:** 110g/day × 25 years = extremely high lifetime dose (nearly 10× the risk threshold). Developing CLD is expected; the surprise is that only 10–15% of such drinkers progress to cirrhosis without co-factors. > **Reference:** EASL CPG on Alcohol-Related Liver Disease, *J Hepatol* 2018; AASLD Guidance on Alcohol-Associated Liver Disease, *Hepatology* 2023. --- **Q6. In summary → examination findings. After Hx & Examination → Differential. CLD → other causes in history (autoimmune, ethanol...)** **Answer:** **Systematic approach to CLD aetiology from History + Examination:** **From History — Aetiological clues:** | Aetiology | Key Historical Feature | |---|---| | Alcoholic | Quantified alcohol (>30g/day >5 years), parotid enlargement, Dupuytren's | | HBV | Perinatal exposure, endemic area, prior transfusion, tattooing, IVDU | | HCV | IVDU, needle-stick, prior transfusion (pre-1992 screening) | | NAFLD/MAFLD | Metabolic syndrome (obesity, T2DM, dyslipidaemia, HTN) | | Autoimmune Hepatitis (AIH) | Young/middle-aged female, other autoimmune disease (thyroiditis, IBD, RA), fluctuating jaundice | | PBC | Middle-aged female, pruritus preceding jaundice, sicca symptoms, xanthelasma | | PSC | Male, IBD (UC > CD), recurrent cholangitis | | Wilson's Disease | Age <40, neuropsychiatric features, Kayser-Fleischer rings, haemolytic anaemia | | Haemochromatosis | Diabetes + "bronze diabetes", arthropathy (2nd-3rd MCP), hypogonadism, cardiomyopathy | | α1-AT deficiency | Emphysema + liver disease, non-smoker, family history | | Budd-Chiari | Thrombophilia risk factors, IVC obstruction symptoms | **From Examination — Stigmata pointing to specific aetiologies:** - Dupuytren's contracture, parotid enlargement, loss of body hair, testicular atrophy → Alcohol. - Kayser-Fleischer rings (slit-lamp) → Wilson's disease. - Xanthelasma + scratch marks → PBC. - Slate-grey skin pigmentation + hepatomegaly → Haemochromatosis. - Emphysematous chest + clubbing → α1-AT deficiency. > **Reference:** Harrison's Principles of Internal Medicine, 22nd ed., Ch. 429 (Cirrhosis). --- **Q7. Ascites → due to decreased liver synthetic function. Portal vein thrombosis → causes UGI bleed but NOT ascites. Explain.** **Answer:** **Why PVT causes UGI bleed but typically NOT ascites:** Portal vein thrombosis causes **pre-hepatic portal hypertension**. The key distinction: - In **pre-hepatic** PVT: Portal pressure is elevated upstream of the liver; but **hepatic synthetic function is normal** (the liver parenchyma is intact and receives adequate arterial blood). Sinusoidal pressure and hepatic venous pressure are NOT elevated. Therefore, the oncotic-hydrostatic balance within the liver sinusoids (the driver of ascites formation) is preserved. UGI bleeding (varices) occurs because the portal-systemic collateral pathways open under elevated portal pressure. - In **cirrhotic portal hypertension** (sinusoidal/post-sinusoidal): Both portal pressure AND sinusoidal hydrostatic pressure are elevated. Combined with hypoalbuminaemia (reduced oncotic pressure), RAAS activation, and splanchnic vasodilation → ascites forms via Starling forces imbalance + sodium/water retention. **The "overflow vs. underfill" debate:** - Classic "underfill theory": reduced plasma oncotic pressure → fluid leaks → reduced effective circulatory volume → RAAS activation. - Modern "overflow theory": Primary renal sodium retention (peripheral arterial vasodilation hypothesis, Schrier et al.) → volume expansion → ascites. - Current consensus: **Splanchnic arterial vasodilation** (nitric oxide-mediated) → reduced effective arterial blood volume → baroreceptor-mediated RAAS/SNS activation → renal sodium and water retention → ascites + oedema. This requires BOTH portal hypertension AND hepatic dysfunction. **Clinical pearl:** A patient with isolated PVT (e.g., from septic thrombosis) rarely develops ascites unless there is concurrent hepatocellular disease. > **Reference:** Schrier RW et al. (*NEJM* 1988); Ginès P & Schrier RW (*NEJM* 2009). --- **Q8. Basal rate = 80% of total daily dose, in TPN over 24hr; bolus → in fluid. 30–34 = basal; 50 = regular. (Insulin management in CLD)** **Answer:** This refers to **insulin management in cirrhosis-related diabetes (Hepatogenous Diabetes)** or management of pre-existing diabetes in CLD, particularly when a patient is on TPN/parenteral nutrition. **Hepatogenous Diabetes:** - Occurs in 30–60% of cirrhotics; caused by peripheral insulin resistance + impaired hepatic glucose metabolism + decreased incretin response. - Differs from T2DM: less macrovascular risk, more HE risk (due to hypoglycaemia from impaired gluconeogenesis), and distinct management. **Insulin management in CLD + TPN:** **Rule: In TPN, 80% of the total daily insulin dose is given as basal (added to TPN bag over 24 hours); 20% is given as correction boluses in IV fluid or subcutaneously.** - Target glucose: **140–180 mg/dL** (7.8–10 mmol/L) in most hospitalised patients (ADA 2024). - In cirrhosis, **hypoglycaemia risk is high** (impaired glycogenolysis + gluconeogenesis) — tighter targets (<140) are NOT recommended. - **Regular insulin** (30–34 units basal) added to TPN bag; regular insulin (50 units) may refer to correction scale. - Monitor glucose q4–6 hourly during TPN. **Oral agents in cirrhosis:** - **Metformin:** Contraindicated in Child C (lactic acidosis risk). - **Sulphonylureas:** High hypoglycaemia risk; avoid. - **SGLT2i:** Avoid (risk of euglycaemic DKA, UTI in immunocompromised). - **Insulin** remains the safest agent in advanced CLD. > **Reference:** ADA Standards of Care in Diabetes 2024, Section 16 (Diabetes in Hospital); EASL CPG Decompensated Cirrhosis 2018. --- **Q9. DDP → Decompensated CLD / CTD / Malnutrition / Disseminated TB / Disseminated Malignancy (ovarian tumour). Examination → PR examination, Breast examination necessary in ascites.** **Answer:** **Complete differential diagnosis of ascites — SAAG-based framework:** **High SAAG (≥1.1 g/dL) — Portal hypertension-related:** - Cirrhosis (most common, ~80%) - Alcoholic hepatitis - Cardiac ascites (right heart failure, constrictive pericarditis, tricuspid regurgitation) - Budd-Chiari Syndrome - Sinusoidal obstruction syndrome (SOS/VOD) - Massive hepatic metastases - Portal vein thrombosis (without cirrhosis — rare to cause ascites) **Low SAAG (<1.1 g/dL) — Non-portal hypertension:** - Peritoneal TB (most important in Nepal/South Asia) - Peritoneal carcinomatosis (ovarian, gastric, colorectal, breast, pancreatic) - Mesothelioma - Pancreatitis / pancreatic ascites - Lymphatic leak (chylous ascites) - Nephrotic syndrome (SAAG low, protein low) - Serositis (SLE, other CTD) **Why PR and breast examination are mandatory in unexplained ascites:** In any woman presenting with ascites without obvious liver disease, **ovarian malignancy** (Krukenberg tumours, papillary serous carcinoma) must be excluded —
cirrhosis decompensation ascites prognosis mortality
cirrhosis malnutrition sarcopenia mortality outcome
alcohol liver disease threshold dose guidelines
\"Budd-Chiari syndrome\" diagnosis treatment guidelines
cirrhosis diabetes insulin management hepatogenous
ls -la /home/daytona/workspace/ 2>/dev/null || echo "workspace empty or not found"
mkdir -p /home/daytona/workspace/cld-qa-bank && ls /home/daytona/skills/docx/
~/cld-qa-bank/generate_qa_bank.js
const {
Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
HeadingLevel, AlignmentType, BorderStyle, WidthType, ShadingType,
VerticalAlign, LevelFormat, PageNumber, PageBreak,
Header, Footer, TabStopType, TabStopPosition
} = require('docx');
const fs = require('fs');
// ── Color palette ──────────────────────────────────────────────────────────
const TEAL = "1A6B72"; // heading backgrounds
const TEAL_LIGHT = "E8F4F5"; // answer block shading
const AMBER = "B8520A"; // Q label text
const DARK = "1C1C1C"; // body text
const MID_GRAY = "555555"; // sub-labels
const BORDER_CLR = "AECFD1"; // table borders
// ── Numbering (bullets & numbered lists) ──────────────────────────────────
const NUMBERING = {
config: [
{
reference: "bullet1",
levels: [{
level: 0, format: LevelFormat.BULLET, text: "\u2022",
alignment: AlignmentType.LEFT,
style: {
paragraph: { indent: { left: 540, hanging: 360 } },
run: { font: "Arial", size: 20 }
}
},{
level: 1, format: LevelFormat.BULLET, text: "\u25E6",
alignment: AlignmentType.LEFT,
style: {
paragraph: { indent: { left: 900, hanging: 360 } },
run: { font: "Arial", size: 20 }
}
}]
},
{
reference: "numbered1",
levels: [{
level: 0, format: LevelFormat.DECIMAL, text: "%1.",
alignment: AlignmentType.LEFT,
style: {
paragraph: { indent: { left: 540, hanging: 360 } },
run: { font: "Arial", size: 20 }
}
}]
}
]
};
// ── Helper: body paragraph ─────────────────────────────────────────────────
function body(text, opts = {}) {
const runs = [];
if (opts.bold) runs.push(new TextRun({ text, font: "Arial", size: 20, bold: true, color: opts.color || DARK }));
else runs.push(new TextRun({ text, font: "Arial", size: 20, color: opts.color || DARK }));
return new Paragraph({
children: runs,
spacing: { after: opts.spaceAfter !== undefined ? opts.spaceAfter : 80, before: opts.spaceBefore || 0 },
alignment: opts.align || AlignmentType.LEFT,
});
}
// ── Helper: mixed-run paragraph (array of {text, bold, italic, color}) ─────
function mixedPara(runs, opts = {}) {
const children = runs.map(r =>
new TextRun({
text: r.text,
font: "Arial",
size: opts.size || 20,
bold: r.bold || false,
italics: r.italic || false,
color: r.color || DARK,
underline: r.underline ? {} : undefined,
})
);
return new Paragraph({
children,
spacing: { after: opts.spaceAfter !== undefined ? opts.spaceAfter : 80, before: opts.spaceBefore || 0 },
alignment: opts.align || AlignmentType.LEFT,
});
}
// ── Helper: bullet paragraph ───────────────────────────────────────────────
function bullet(text, level = 0, bold = false) {
const parts = splitBoldMarkers(text, bold);
return new Paragraph({
numbering: { reference: "bullet1", level },
children: parts,
spacing: { after: 60 },
});
}
// ── Helper: numbered paragraph ────────────────────────────────────────────
function numbered(text, bold = false) {
const parts = splitBoldMarkers(text, bold);
return new Paragraph({
numbering: { reference: "numbered1", level: 0 },
children: parts,
spacing: { after: 60 },
});
}
// ── Helper: parse **bold** markers into TextRun array ─────────────────────
function splitBoldMarkers(text, defaultBold = false) {
const segments = text.split(/\*\*(.*?)\*\*/g);
return segments.map((seg, i) =>
new TextRun({
text: seg,
font: "Arial",
size: 20,
bold: i % 2 === 1 ? true : defaultBold,
color: DARK,
})
);
}
// ── Helper: blank line ─────────────────────────────────────────────────────
function blank(space = 80) {
return new Paragraph({ children: [new TextRun({ text: "" })], spacing: { after: space } });
}
// ── Helper: section heading (Q label + question text) ─────────────────────
function questionBlock(num, title) {
return [
new Paragraph({
children: [
new TextRun({ text: `Q${num}. `, font: "Arial", size: 24, bold: true, color: AMBER }),
new TextRun({ text: title, font: "Arial", size: 24, bold: true, color: DARK }),
],
spacing: { before: 320, after: 80 },
shading: { type: ShadingType.CLEAR, color: "auto", fill: TEAL_LIGHT },
border: {
left: { style: BorderStyle.THICK, size: 12, color: TEAL },
},
indent: { left: 160 },
}),
];
}
// ── Helper: shaded answer header ──────────────────────────────────────────
function answerHeader() {
return new Paragraph({
children: [new TextRun({ text: "ANSWER", font: "Arial", size: 18, bold: true, color: "FFFFFF", allCaps: true })],
shading: { type: ShadingType.CLEAR, color: "auto", fill: TEAL },
spacing: { before: 80, after: 0 },
indent: { left: 0 },
});
}
// ── Helper: correction callout ────────────────────────────────────────────
function correctionNote(text) {
return new Paragraph({
children: [
new TextRun({ text: "\u26A0 CORRECTION / ADDITION: ", font: "Arial", size: 18, bold: true, color: "C0392B" }),
new TextRun({ text, font: "Arial", size: 18, italics: true, color: "C0392B" }),
],
shading: { type: ShadingType.CLEAR, color: "auto", fill: "FADBD8" },
spacing: { before: 80, after: 80 },
indent: { left: 160 },
border: { left: { style: BorderStyle.SINGLE, size: 6, color: "C0392B" } },
});
}
// ── Helper: reference line ────────────────────────────────────────────────
function refLine(text) {
return new Paragraph({
children: [
new TextRun({ text: "\u25B6 Reference: ", font: "Arial", size: 17, bold: true, color: MID_GRAY }),
new TextRun({ text, font: "Arial", size: 17, italics: true, color: MID_GRAY }),
],
spacing: { before: 100, after: 120 },
indent: { left: 160 },
});
}
// ── Helper: sub-heading within answer ─────────────────────────────────────
function subHead(text) {
return new Paragraph({
children: [new TextRun({ text, font: "Arial", size: 21, bold: true, color: TEAL })],
spacing: { before: 160, after: 60 },
});
}
// ── Helper: simple 2-col table ────────────────────────────────────────────
function makeTable(headers, rows, colWidths) {
const borderOpts = { style: BorderStyle.SINGLE, size: 4, color: BORDER_CLR };
const allBorders = { top: borderOpts, bottom: borderOpts, left: borderOpts, right: borderOpts, insideHorizontal: borderOpts, insideVertical: borderOpts };
const headerRow = new TableRow({
tableHeader: true,
children: headers.map((h, i) =>
new TableCell({
width: { size: colWidths[i], type: WidthType.DXA },
shading: { type: ShadingType.CLEAR, fill: TEAL },
verticalAlign: VerticalAlign.CENTER,
children: [new Paragraph({
children: [new TextRun({ text: h, font: "Arial", size: 18, bold: true, color: "FFFFFF" })],
spacing: { before: 60, after: 60 },
alignment: AlignmentType.LEFT,
})],
})
),
});
const dataRows = rows.map(row =>
new TableRow({
children: row.map((cell, i) =>
new TableCell({
width: { size: colWidths[i], type: WidthType.DXA },
verticalAlign: VerticalAlign.TOP,
children: [new Paragraph({
children: splitBoldMarkers(cell),
spacing: { before: 40, after: 40 },
alignment: AlignmentType.LEFT,
})],
})
),
})
);
return new Table({
borders: allBorders,
rows: [headerRow, ...dataRows],
width: { size: 9200, type: WidthType.DXA },
margins: { top: 60, bottom: 60, left: 80, right: 80 },
});
}
// ── Cover page ─────────────────────────────────────────────────────────────
function coverPage() {
return [
blank(600),
new Paragraph({
children: [new TextRun({ text: "COMPREHENSIVE FACULTY Q&A BANK", font: "Arial", size: 52, bold: true, color: TEAL, allCaps: true })],
alignment: AlignmentType.CENTER,
spacing: { after: 160 },
}),
new Paragraph({
children: [new TextRun({ text: "Decompensated Chronic Liver Disease", font: "Arial", size: 36, bold: false, color: DARK })],
alignment: AlignmentType.CENTER,
spacing: { after: 120 },
}),
new Paragraph({
children: [new TextRun({ text: "Compiled from Previous Case Presentation Sessions", font: "Arial", size: 24, italics: true, color: MID_GRAY })],
alignment: AlignmentType.CENTER,
spacing: { after: 60 },
}),
new Paragraph({
children: [new TextRun({ text: "Postgraduate Internal Medicine", font: "Arial", size: 24, italics: true, color: MID_GRAY })],
alignment: AlignmentType.CENTER,
spacing: { after: 400 },
}),
new Paragraph({
children: [new TextRun({ text: "\u2500".repeat(50), font: "Arial", size: 20, color: TEAL })],
alignment: AlignmentType.CENTER,
spacing: { after: 300 },
}),
new Paragraph({
children: [new TextRun({ text: "Reviewed & Improved — June 2026", font: "Arial", size: 22, bold: true, color: MID_GRAY })],
alignment: AlignmentType.CENTER,
spacing: { after: 80 },
}),
new Paragraph({
children: [new TextRun({ text: "All answers cross-checked against: Harrison's 22e (2025), Sleisenger & Fordtran 11e,", font: "Arial", size: 19, italics: true, color: MID_GRAY })],
alignment: AlignmentType.CENTER,
spacing: { after: 60 },
}),
new Paragraph({
children: [new TextRun({ text: "Yamada Gastroenterology 7e, EASL / ESPEN / AASLD guidelines 2018-2024,", font: "Arial", size: 19, italics: true, color: MID_GRAY })],
alignment: AlignmentType.CENTER,
spacing: { after: 60 },
}),
new Paragraph({
children: [new TextRun({ text: "and recent PubMed literature (2021-2026)", font: "Arial", size: 19, italics: true, color: MID_GRAY })],
alignment: AlignmentType.CENTER,
spacing: { after: 400 },
}),
new Paragraph({ children: [new PageBreak()], spacing: { after: 0 } }),
];
}
// ══════════════════════════════════════════════════════════════════════════
// CASE HEADER
// ══════════════════════════════════════════════════════════════════════════
function caseHeader() {
return [
new Paragraph({
children: [new TextRun({ text: "FROM RABIN MAHARJAN'S CASE", font: "Arial", size: 26, bold: true, color: "FFFFFF", allCaps: true })],
shading: { type: ShadingType.CLEAR, fill: TEAL },
alignment: AlignmentType.CENTER,
spacing: { before: 160, after: 60 },
}),
new Paragraph({
children: [new TextRun({ text: "46F | Ascites + Bilateral Leg Swelling + Shortness of Breath", font: "Arial", size: 22, italics: true, color: MID_GRAY })],
shading: { type: ShadingType.CLEAR, fill: TEAL_LIGHT },
alignment: AlignmentType.CENTER,
spacing: { before: 0, after: 280 },
}),
];
}
// ══════════════════════════════════════════════════════════════════════════
// Q1
// ══════════════════════════════════════════════════════════════════════════
function q1() {
return [
...questionBlock(1, "If ascites is the first presentation it carries a bad prognosis, but if UGI bleed is the first presentation the prognosis is relatively better. Explain this paradox."),
answerHeader(),
blank(60),
subHead("Background: The D'Amico Staging System"),
body("The natural history of cirrhosis was systematically mapped by D'Amico et al. (J Hepatol 2014) into four clinical stages defined by the presence or absence of varices, ascites, and variceal bleeding. Each stage carries a distinct 1-year mortality, providing the evidence base for this 'paradox.'"),
blank(60),
makeTable(
["Stage", "Clinical Features", "1-Year Mortality"],
[
["Stage 1", "Compensated: no varices, no ascites", "~1%"],
["Stage 2", "Compensated: varices present, no ascites", "~3.4%"],
["Stage 3", "Decompensated: ascites (±varices, no bleeding)", "~20%"],
["Stage 4", "Decompensated: variceal bleeding (±ascites)", "**~57% if ascites also present**"],
["Stage 4 (bleeding alone)", "Variceal bleed, no ascites (preserved function)", "**~5-10% at 6 weeks** (Child A)"],
],
[1200, 4000, 2500]
),
blank(100),
subHead("Why Ascites as First Decompensation Carries a Worse Prognosis"),
bullet("Ascites requires convergence of **three pathophysiological mechanisms**: severe portal hypertension (HVPG ≥12 mmHg), hepatic synthetic failure (hypoalbuminaemia reducing oncotic pressure), and neurohormonal dysregulation (RAAS/SNS/ADH activation via splanchnic vasodilation)."),
bullet("1-year mortality after first ascites: approximately **20%**; 5-year mortality after any decompensation reaches **up to 85%** without transplantation (Symptom to Diagnosis 4e)."),
bullet("Ascites is a harbinger of further complications in a downward cascade: SBP (25-30%/year), hepatorenal syndrome (18%/year), hepatic encephalopathy."),
bullet("Median survival after decompensation is approximately **2 years**, compared to **12 years** for compensated cirrhosis (Yamada Gastroenterology 7e; D'Amico et al. 2006 systematic review of >1500 patients)."),
blank(80),
subHead("Why Variceal Bleed as First Decompensation Carries a Relatively Better Prognosis"),
bullet("Variceal bleeding can occur at HVPG ≥12 mmHg (the threshold for variceal rupture) even in **Child A disease with preserved synthetic function** -- it does not require the degree of parenchymal failure that ascites demands."),
bullet("A Child A patient with their first variceal bleed has a 6-week mortality of approximately 5-10%. This is fundamentally different from a Child C patient with ascites."),
bullet("**Important nuance:** The prognosis of variceal bleeding deteriorates sharply when ascites coexists -- 1-year mortality rises to ~57% (Stage 4 with both features). The 'better prognosis' applies only when bleeding is the isolated first event in a compensated patient."),
bullet("The CANONIC study (Moreau et al., Hepatology 2013) confirmed that among all decompensation events, ascites alone conferred the worst median transplant-free survival."),
blank(80),
correctionNote("The original stated '5-year mortality is 50%' after first ascites. This underestimates severity. The more accurate figure is 5-year mortality approaching 85% after any decompensation (without transplantation). The 20% figure is specifically the 1-year mortality after first ascites presentation. Distinguish these time points in exam answers."),
blank(80),
refLine("D'Amico G et al. J Hepatol 2014; Moreau R et al. (CANONIC). Hepatology 2013; Symptom to Diagnosis 4e (McGraw Hill) p.7820; Yamada Gastroenterology 7e, Section 100."),
blank(100),
];
}
// ══════════════════════════════════════════════════════════════════════════
// Q2
// ══════════════════════════════════════════════════════════════════════════
function q2() {
return [
...questionBlock(2, "Add history of malnutrition to the assessment. Why is it important, and how is it evaluated in cirrhosis?"),
answerHeader(),
blank(60),
subHead("Prevalence and Prognostic Weight"),
bullet("Malnutrition is present in **50-90% of cirrhotics** (rising with Child-Pugh class) and is an independent predictor of mortality, infection risk, hepatic encephalopathy, poor wound healing, and post-transplant outcomes."),
bullet("A 2025 systematic review (Becchetti et al., Hepatol Commun 2025; PMID 41118290) confirmed sarcopenia and frailty independently predict decompensation events even in compensated cirrhosis."),
bullet("A 2026 meta-analysis (Ahmed et al., Clin Nutr ESPEN 2026; PMID 41285365) confirmed that oral nutritional therapy in cirrhosis significantly improves clinical and functional outcomes."),
blank(80),
subHead("Pathophysiology of Malnutrition in Cirrhosis"),
bullet("**Accelerated starvation phenotype:** Reduced glycogen stores mean an overnight fast is metabolically equivalent to a 2-3 day fast in a healthy person -- hence the importance of late evening snacking."),
bullet("**Protein catabolism:** Reduced branched-chain amino acids (BCAA) and elevated aromatic amino acids (AAA) -- the Fischer ratio (BCAA:AAA) is reduced -- contributes to hyperammonaemia and hepatic encephalopathy risk."),
bullet("**Zinc deficiency:** Impairs the urea cycle, worsening hyperammonaemia."),
bullet("**Fat malabsorption** (cholestatic disease): Deficiency of fat-soluble vitamins A, D, E, K."),
bullet("**Sarcopenia** (reduced skeletal muscle mass): Independently predicts 6-month mortality (Montano-Loza et al., Hepatology 2012). Muscle serves as the primary ammonia-detoxifying organ outside the liver (via glutamine synthesis), so its loss accelerates encephalopathy."),
blank(80),
subHead("Assessment Tools"),
makeTable(
["Tool", "What It Measures", "Notes"],
[
["**RFH-GA** (Royal Free Hospital Global Assessment)", "BMI, mid-arm circumference, dietary intake", "Validated specifically for cirrhosis; preferred over generic SGA"],
["**Handgrip Strength** (dynamometry)", "Functional muscle strength as sarcopenia proxy", "< 30 kg (men), < 20 kg (women) = significant; easy bedside tool"],
["**MAMC** (Mid-Arm Muscle Circumference)", "Lean muscle mass; unaffected by oedema", "MAMC = MAC - (pi x triceps skinfold)"],
["**CT L3 Skeletal Muscle Index**", "Gold standard for sarcopenia quantification", "Research/pre-transplant use; requires CT already being done"],
["**BIA** (Bioimpedance Analysis)", "Lean body mass estimate", "Accuracy reduced in significant ascites -- use with caution"],
],
[2000, 3200, 2500]
),
blank(100),
subHead("Management Principles"),
bullet("Caloric target: **35-40 kcal/kg/day** (using dry weight or adjusted body weight in obese patients)."),
bullet("Protein target: **1.2-1.5 g/kg/day** -- protein restriction is **obsolete** in cirrhosis and harmful (worsens sarcopenia and encephalopathy)."),
bullet("**Late Evening Snack (LES):** 50 g complex carbohydrate at bedtime (e.g., bread, crackers) -- directly counteracts the accelerated starvation state by reducing overnight fasting duration. ESPEN Grade A recommendation."),
bullet("BCAA supplementation: Indicated when patients cannot tolerate adequate protein due to encephalopathy -- replaces AAA-predominant protein with BCAA-rich supplements. **Not indicated routinely** in all cirrhotics."),
bullet("Zinc supplementation: 220 mg zinc sulfate BD if deficiency suspected -- improves encephalopathy and urea cycle function."),
blank(80),
refLine("ESPEN Guidelines on Liver Disease, Clin Nutr 2019; Montano-Loza AJ et al. Hepatology 2012; Becchetti C et al. PMID 41118290 (2025); Ahmed HM et al. PMID 41285365 (2026)."),
blank(100),
];
}
// ══════════════════════════════════════════════════════════════════════════
// Q3
// ══════════════════════════════════════════════════════════════════════════
function q3() {
return [
...questionBlock(3, "What is Budd-Chiari Syndrome (BCS)? What are its causes? What is HVOTO?"),
answerHeader(),
blank(60),
subHead("Definition"),
body("Budd-Chiari Syndrome (BCS) is the obstruction of hepatic venous outflow at any level -- from the small hepatic venules to the junction of the hepatic veins with the inferior vena cava (IVC) or the terminal IVC itself. Cardiac causes of hepatic congestion (constrictive pericarditis, right heart failure, tricuspid regurgitation) are excluded from the BCS definition."),
body("HVOTO = Hepatic Venous Outflow Tract Obstruction. This is the pathophysiological umbrella term covering BCS at all anatomical levels."),
blank(80),
subHead("Classification"),
bullet("**Primary BCS:** Obstruction arises from within the vein itself (thrombosis due to thrombophilia, venous anomaly)."),
bullet("**Secondary BCS:** Obstruction caused by a lesion outside the veins -- tumour invasion (HCC, renal cell carcinoma), compression by cysts, or alveolar echinococcosis."),
blank(80),
subHead("Epidemiology -- Nepal-Specific Context"),
bullet("BCS is rare globally (incidence ~1.4-2.2 per million in Europe) but has significantly higher prevalence in South and East Asia."),
bullet("**In Nepal specifically:** BCS accounted for **17% of all hospital admissions for liver-related disease** in Kathmandu (1990-1992), per Sleisenger & Fordtran 11e. An unexplained association with extreme poverty has been documented in both Nepal and China, suggesting nutritional/infectious co-factors beyond thrombophilia alone."),
bullet("This makes BCS a far more relevant differential in the Nepali clinical context than Western guidelines might suggest."),
blank(80),
subHead("Causes (Mnemonic: MPN-PHAB)"),
makeTable(
["Cause", "Notes"],
[
["**Myeloproliferative Neoplasms (MPN)**", "Most common in Western patients; accounts for up to 41% of primary BCS. JAK2 V617F mutation found in >75% of MPN-related BCS. Polycythaemia vera is the single largest entity. Portal hypertension may normalize blood counts, masking the diagnosis."],
["**Paroxysmal Nocturnal Haemoglobinuria (PNH)**", "Clonal disorder; test: flow cytometry for CD55/CD59 loss. Rarely implicated in Asian BCS."],
["**Hypercoagulable states**", "Antiphospholipid syndrome, Factor V Leiden, Prothrombin G20210A, Protein C/S/ATIII deficiency. Note: Protein C/S/ATIII can be spuriously low in liver disease -- interpret with caution."],
["**Abdominal malignancy**", "HCC (direct invasion or tumour thrombus), renal cell carcinoma, adrenal carcinoma."],
["**Behcet's disease**", "Particularly causes IVC-level obstruction."],
["**OCP/Pregnancy**", "~7% of reported cases associated with pregnancy/puerperium. OCPs are a recognised risk factor."],
["**Hyperhomocysteinaemia / MTHFR C677T**", "Common in Chinese patients; may be relevant in Nepali population given dietary folate deficiency."],
],
[2500, 6000]
),
blank(100),
subHead("Clinical Triad"),
bullet("Abdominal pain + hepatomegaly + **massive ascites** (hallmark triad)."),
bullet("Ascites in BCS is typically **high SAAG (>=1.1 g/dL) but high protein (>2.5 g/dL)** -- unlike cirrhotic ascites where protein is usually <2.5 g/dL. This protein-rich, high-SAAG pattern is a key diagnostic clue."),
bullet("Caudate lobe hypertrophy is a characteristic finding (its independent venous drainage via accessory veins directly to the IVC allows it to remain perfused while other segments are congested)."),
blank(80),
subHead("Diagnosis"),
bullet("**Doppler USG (first-line):** Absent/reversed hepatic vein flow, spider-web pattern of intrahepatic collaterals, caudate lobe hypertrophy."),
bullet("**Triphasic CT / MRI:** Peripheral hepatic congestion with central (caudate) sparing, 'flip-flop' enhancement (periphery hyperdense in portal phase, caudate hyperdense in equilibrium phase), absent hepatic veins."),
bullet("**Workup for underlying cause:** JAK2 V617F mutation, PNH screen (flow cytometry), antiphospholipid antibodies, thrombophilia panel, bone marrow biopsy if MPN suspected."),
blank(80),
correctionNote("The original stated MPN accounts for '40-50%' of BCS. The textbook figure (Sleisenger & Fordtran) is 'up to 41%.' The original also lacked the Nepal-specific epidemiological data, which is critically relevant for this postgraduate audience. BCS accounted for 17% of liver-related hospital admissions in Kathmandu -- this makes BCS a frontline differential in Nepal, not a rare consideration."),
blank(80),
refLine("Sleisenger & Fordtran GI & Liver Disease 11e, Ch. 85 (pp. 1321-1327); EASL CPG Vascular Diseases of the Liver, J Hepatol 2016; Furuichi Y et al. Guidelines BCS Japan. Hepatol Res 2024 (PMID 39364631)."),
blank(100),
];
}
// ══════════════════════════════════════════════════════════════════════════
// Q4
// ══════════════════════════════════════════════════════════════════════════
function q4() {
return [
...questionBlock(4, "How do you assess BMI and nutritional status in an oedematous or ascitic patient?"),
answerHeader(),
blank(60),
subHead("The Problem with Standard BMI in Fluid-Overloaded Patients"),
body("Standard BMI (weight / height^2) is unreliable when measured weight includes ascites and peripheral oedema. A patient with 10 L of ascites has 10 kg of fluid artificially inflating their BMI, masking underlying sarcopenic malnutrition. ESPEN 2019 explicitly recommends against using BMI alone in cirrhotics."),
blank(80),
subHead("Practical Approach: Estimating Dry Weight"),
bullet("**Ascites volume estimation:**"),
bullet("Mild (no flank dullness on supine): ~1-2 L", 1),
bullet("Moderate (detectable on examination): ~4-6 L", 1),
bullet("Tense (massive, shifting dullness, fluid thrill): ~8-14 L", 1),
bullet("**Peripheral oedema estimation:** Approximately 1-2 L per grade (grade 1 = pretibial only, grade 4 = above knee / thigh)."),
bullet("**Formula:** Estimated dry weight = Actual weight - Ascites weight - Oedema weight. Use this dry weight for BMI and nutritional calculations (protein, caloric targets)."),
bullet("**Post-paracentesis weight:** Most accurate approximation -- weigh the patient immediately after large-volume paracentesis."),
blank(80),
subHead("Preferred Nutritional Assessment Tools in Cirrhosis"),
makeTable(
["Tool", "Advantage", "Limitation"],
[
["**RFH-GA**", "Validated for cirrhosis; includes dietary intake, MAC, BMI", "Requires trained assessor"],
["**Handgrip Strength**", "Bedside; unaffected by fluid; functional marker; prognostic", "Age/sex-dependent norms needed"],
["**MAMC** (mid-arm muscle circumference)", "Unaffected by fluid distribution", "Requires calliper; observer variability"],
["**CT L3 SMI**", "Gold standard for sarcopenia", "Radiation; cost; only if CT already done"],
["**BIA**", "Non-invasive lean mass estimate", "Inaccurate when ascites > ~5 L"],
],
[2200, 3000, 2500]
),
blank(100),
subHead("Clinical Pearl"),
body("When a patient has significant ascites and you need their nutritional status for management planning, the single best bedside tool is handgrip dynamometry. It takes 30 seconds, requires no correction for fluid status, and has established prognostic thresholds in cirrhosis (<30 kg force in men, <20 kg in women = significant sarcopenia)."),
blank(80),
refLine("ESPEN Guidelines on Liver Disease, Clin Nutr 2019; RFH-Global Assessment tool (Morgan et al., Gut 2006)."),
blank(100),
];
}
// ══════════════════════════════════════════════════════════════════════════
// Q5
// ══════════════════════════════════════════════════════════════════════════
function q5() {
return [
...questionBlock(5, "What is the minimum amount and duration of alcohol required to develop chronic liver disease (CLD)?"),
answerHeader(),
blank(60),
subHead("Threshold Quantities (EASL ALD Guidelines 2023 / AASLD 2023)"),
makeTable(
["Parameter", "Men", "Women"],
[
["Threshold for 'significant' alcohol intake (guidelines)", ">21 units/week (>210 g/week)", ">14 units/week (>140 g/week)"],
["**Risk threshold for ALD** (duration: >5 years)", ">30 g/day", ">20 g/day"],
["**High risk for cirrhosis** (duration: >10 years)", ">60-80 g/day", ">20-40 g/day"],
],
[3000, 2600, 2600]
),
blank(100),
body("Note: 1 unit (UK) = 8-10 g pure alcohol. 1 standard drink (USA) = 14 g. 1 standard drink (WHO) = 10 g."),
blank(80),
subHead("Why Women Are More Vulnerable (Key Exam Point)"),
bullet("**Lower gastric ADH activity:** Less first-pass metabolism of ethanol in the stomach, resulting in higher blood alcohol levels per gram consumed."),
bullet("**Higher body fat percentage:** Smaller volume of distribution for ethanol (it is water-soluble), resulting in higher peak blood alcohol concentration."),
bullet("**Oestrogen-mediated hepatotoxicity:** Oestrogen upregulates hepatic endotoxin sensitivity and enhances oxidative stress in hepatocytes."),
bullet("**Consequence:** Women develop ALD at lower doses, shorter durations, and with faster progression to cirrhosis compared to men."),
blank(80),
subHead("Why Only 10-15% of Heavy Drinkers Develop Cirrhosis"),
body("This is one of the most commonly asked exam questions. Despite >80% of heavy drinkers developing steatosis and ~30% developing alcoholic hepatitis, only 10-15% progress to cirrhosis. Modifying factors include:"),
bullet("**PNPLA3 I148M polymorphism:** The most studied genetic risk modifier; homozygous carriers have significantly higher fibrosis risk."),
bullet("**TM6SF2 E167K variant:** Second major genetic modifier identified in genome-wide studies."),
bullet("**Metabolic co-factors:** Obesity and type 2 diabetes dramatically amplify fibrogenic risk (multiplicative, not additive)."),
bullet("**Viral co-infection:** Concurrent HCV markedly accelerates fibrosis progression."),
bullet("**Drinking pattern:** Binge drinking (>60 g in a single session) is more hepatotoxic than an equivalent daily intake distributed across the week -- likely related to peak acetaldehyde and oxidative stress."),
bullet("**Nutritional status:** Malnutrition worsens fibrogenic risk."),
blank(80),
subHead("Application to This Case"),
body("At 110 g/day for 25 years, this patient's lifetime alcohol dose is approximately 10x the minimum risk threshold. With co-existing malnutrition, the development of cirrhosis is expected. The 'surprise' is why more patients at this dose level do not develop cirrhosis -- highlighting the role of genetic susceptibility."),
blank(80),
correctionNote("The EASL guidelines were updated in 2023 (AASLD Hepatology 2023 also updated). The original referenced only the 2018 guidelines. The updated guidance reinforces the same thresholds but adds stronger emphasis on any level of drinking increasing fibrosis risk progressively, with no absolutely 'safe' threshold for those with genetic susceptibility."),
blank(80),
refLine("EASL CPG on Alcohol-Related Liver Disease, J Hepatol 2018; AASLD Guidance Alcohol-Associated Liver Disease, Hepatology 2023; Harrison's 22e (2025), Ch. on Liver Disease."),
blank(100),
];
}
// ══════════════════════════════════════════════════════════════════════════
// Q6
// ══════════════════════════════════════════════════════════════════════════
function q6() {
return [
...questionBlock(6, "Summarise the approach to differential diagnosis of CLD: how do history and examination point to specific aetiologies?"),
answerHeader(),
blank(60),
subHead("Step 1: Aetiological Clues from History"),
makeTable(
["Aetiology", "Key Historical Features"],
[
["**Alcohol-related LD**", "Quantified intake >30 g/day (men) / >20 g/day (women) for >5 years; occupational/social history; parotid enlargement; Dupuytren's contracture; history of binge episodes"],
["**HBV**", "Perinatal exposure (endemic area, mother HBsAg+), sexual history, prior blood transfusion (pre-screening era), IVDU, tattooing, travel history; family history of HCC"],
["**HCV**", "IVDU (even historical), needle-stick, transfusion before 1992 (pre-screening), healthcare worker, intranasal drug use"],
["**MAFLD / NAFLD**", "Metabolic syndrome: obesity, T2DM, dyslipidaemia, hypertension; no significant alcohol history; incidental fatty liver on imaging"],
["**Autoimmune Hepatitis (AIH)**", "Young/middle-aged female; other autoimmune conditions (thyroiditis, IBD, RA, vitiligo); fluctuating jaundice; responds to steroids"],
["**Primary Biliary Cholangitis (PBC)**", "Middle-aged female; pruritus preceding jaundice (often years before); sicca syndrome (dry eyes/mouth); xanthelasma; elevated ALP with disproportionately mild AST/ALT"],
["**Primary Sclerosing Cholangitis (PSC)**", "Male predominance; long-standing IBD (UC >> CD); recurrent episodes of cholangitis; elevated ALP, bilirubin"],
["**Wilson's Disease**", "Age <40 (rarely presents after 40 with acute disease); neuropsychiatric features (personality change, dysarthria, tremor); haemolytic anaemia; family history; consanguinity"],
["**Hereditary Haemochromatosis**", "'Bronze diabetes' (diabetes + hyperpigmentation); arthropathy particularly 2nd-3rd MCP joints (pathognomonic); hypogonadism (reduced libido/amenorrhoea); cardiomyopathy/arrhythmia; family history"],
["**Alpha-1-AT Deficiency**", "Emphysema + liver disease combination; non-smoker with COPD; family history; onset in young adults"],
["**Budd-Chiari Syndrome**", "Features of thrombophilia (DVT, PE, arterial clots); MPN symptoms (plethora, pruritis post-bath, splenomegaly); OCP use; recent pregnancy; massive tense ascites as dominant feature"],
],
[2200, 6300]
),
blank(100),
subHead("Step 2: Examination Stigmata Pointing to Specific Aetiologies"),
makeTable(
["Finding", "Aetiological Association"],
[
["Dupuytren's contracture, parotid enlargement, loss of body hair, testicular atrophy, feminising features (gynaecomastia, spider naevi)","**Alcohol** -- feminising features due to impaired hepatic oestrogen metabolism"],
["Kayser-Fleischer rings (requires slit-lamp)", "**Wilson's Disease** -- present in >95% with neurological involvement; only ~50% with hepatic-only presentation"],
["Xanthelasma + scratch marks (excoriations on skin)", "**PBC** -- cholestasis-driven hyperlipidaemia and bile salt deposition in skin"],
["Slate-grey/bronze skin pigmentation + hepatomegaly", "**Hereditary Haemochromatosis** -- iron deposition in melanocytes"],
["Emphysematous chest with young-onset liver disease", "**Alpha-1-AT deficiency**"],
["Periumbilical collaterals (caput medusae)", "Portal hypertension (any cause); LR+ = 9.5 for cirrhosis"],
["Tender hepatomegaly, skin changes post-bath pruritus, plethora", "**Polycythaemia Vera** -- may underlie BCS; portal hypertension normalises blood counts masking PCV"],
["Acanthosis nigricans, obesity, buffalo hump", "**MAFLD** -- metabolic syndrome"],
],
[3800, 4700]
),
blank(100),
correctionNote("The original used 'NAFLD' -- updated 2020 multi-society consensus terminology is MAFLD (Metabolic-Associated Fatty Liver Disease), which is being superseded further by MASLD/MASH (2023 Delphi). For examinations, both NAFLD and MAFLD/MASLD are acceptable; be aware of the terminological evolution and its clinical implications (MASLD criteria are slightly broader and include alcohol up to 30g/week in men)."),
blank(80),
refLine("Harrison's 22e (2025), Ch. 429 (Cirrhosis); Sleisenger & Fordtran 11e; EASL CPG NAFLD/NASH (now updated to MAFLD/MASLD 2023)."),
blank(100),
];
}
// ══════════════════════════════════════════════════════════════════════════
// Q7
// ══════════════════════════════════════════════════════════════════════════
function q7() {
return [
...questionBlock(7, "Portal vein thrombosis (PVT) causes UGI bleed but NOT ascites. Ascites requires decreased liver synthetic function. Explain the mechanism."),
answerHeader(),
blank(60),
subHead("Key Concept: Pre-Hepatic vs. Sinusoidal Portal Hypertension"),
body("Portal hypertension is classified anatomically. The critical difference between PVT (pre-hepatic) and cirrhosis (sinusoidal/post-hepatic) explains this clinical paradox."),
blank(80),
makeTable(
["Feature", "PVT (Pre-Hepatic)", "Cirrhosis (Sinusoidal)"],
[
["Site of obstruction", "Portal vein (upstream of liver)", "Hepatic sinusoids (within liver)"],
["Hepatic parenchyma", "Intact -- normal synthetic function", "Destroyed -- reduced albumin, clotting factors"],
["Sinusoidal hydrostatic pressure", "Normal", "Markedly elevated"],
["RAAS / SNS activation", "Minimal / absent", "Severe -- 'overflow' mechanism"],
["Albumin (oncotic pressure)", "Normal", "Reduced"],
["**Ascites development**", "**Absent (or minimal/transient)**", "**Present -- cardinal feature**"],
["**Variceal bleeding**", "**Present** -- portal pressure >12 mmHg opens collaterals", "**Present**"],
],
[2800, 3000, 3000]
),
blank(100),
subHead("Mechanism of Ascites in Cirrhosis: The Peripheral Arterial Vasodilation Hypothesis (Schrier et al., NEJM 1988)"),
numbered("Hepatic fibrosis + portal hypertension --> splanchnic arterial vasodilation (mediated by **nitric oxide**, prostacyclin, glucagon)."),
numbered("Splanchnic vasodilation reduces 'effective arterial blood volume' despite increased total body water."),
numbered("Baroreceptors sense reduced effective circulating volume --> activate **RAAS** (renin-angiotensin-aldosterone), **SNS** (sympathetic nervous system), and **ADH/vasopressin**."),
numbered("RAAS/SNS activation --> renal sodium and water retention --> volume overload."),
numbered("Simultaneously, hypoalbuminaemia (reduced oncotic pressure) + elevated sinusoidal hydrostatic pressure --> Starling forces overwhelmingly favour fluid movement into the peritoneal cavity."),
numbered("Result: **Ascites and peripheral oedema** (overflow model)."),
blank(80),
subHead("Why PVT Alone Does NOT Cause Ascites"),
bullet("In isolated PVT, the **hepatic sinusoids are unaffected** -- sinusoidal hydrostatic pressure is normal."),
bullet("Hepatic synthetic function is **preserved** -- albumin is normal, so oncotic pressure is maintained."),
bullet("There is no RAAS/SNS activation loop as effective arterial blood volume is normal."),
bullet("Varices develop because portal pressure is elevated upstream (HVPG threshold for variceal bleeding: >=12 mmHg) and collaterals open, but the liver parenchyma is unharmed."),
bullet("**Exception:** PVT on a background of cirrhosis (common -- 10-25% of cirrhotics have PVT) will produce ascites because the underlying cirrhotic physiology is already driving it. This is why PVT is not always 'safe' in cirrhosis."),
blank(80),
subHead("Summary Statement for Exam"),
body("Ascites requires the combination of (1) elevated sinusoidal hydrostatic pressure AND (2) reduced oncotic pressure AND (3) neurohormonal sodium retention. PVT satisfies none of these three conditions in isolation. Variceal bleeding requires only portal pressure >=12 mmHg -- a threshold achievable in pre-hepatic disease with intact liver function.", { bold: false }),
blank(80),
refLine("Schrier RW et al. NEJM 1988;319:1121-1128; Gines P & Schrier RW. NEJM 2009;361:1279-1290; Sleisenger & Fordtran 11e, Ch. 85 (Portal Vein Thrombosis)."),
blank(100),
];
}
// ══════════════════════════════════════════════════════════════════════════
// Q8
// ══════════════════════════════════════════════════════════════════════════
function q8() {
return [
...questionBlock(8, "Describe insulin management in CLD, including the TPN rule (80% basal / 20% bolus) and the approach to hepatogenous diabetes."),
answerHeader(),
blank(60),
subHead("What is Hepatogenous Diabetes?"),
bullet("Diabetes occurring specifically in the setting of cirrhosis; present in **30-60% of cirrhotics**."),
bullet("Distinct from T2DM: less macrovascular risk, less fasting hyperglycaemia, more post-prandial hyperglycaemia (due to impaired hepatic glucose uptake after meals)."),
bullet("Mechanisms: peripheral insulin resistance + impaired hepatic glucose metabolism + porto-systemic shunting bypassing first-pass insulin extraction + reduced incretin response."),
bullet("A 2026 review (El-Azab et al., Clin Exp Med 2026; PMID 42001361) emphasises precision medicine approaches including individualised glycaemic targets based on liver function class."),
blank(80),
subHead("Glucose Targets in Hospitalised Cirrhotic Patients"),
bullet("Target: **140-180 mg/dL (7.8-10 mmol/L)** -- standard for most hospitalised patients (ADA Standards of Care 2024)."),
bullet("**Do NOT aim for tight control (<140 mg/dL) in cirrhosis:** Impaired glycogenolysis and gluconeogenesis dramatically increase hypoglycaemia risk. Even mild hypoglycaemia can precipitate hepatic encephalopathy."),
bullet("In Child C cirrhosis with TPN, monitor glucose **every 4-6 hours** and adjust insulin accordingly."),
blank(80),
subHead("The 80:20 Insulin Rule in TPN"),
body("When a cirrhotic patient requires total parenteral nutrition (TPN):"),
bullet("**80% of total daily insulin requirement** is added directly to the TPN bag as regular (soluble) insulin, delivered continuously over 24 hours = the basal component."),
bullet("**20% of total daily insulin requirement** is given as correction boluses (in IV fluid or subcutaneously) in response to glucose readings exceeding target."),
bullet("This ratio maximises glucose stability with the continuous dextrose load from TPN while preserving a correction pool for hyperglycaemic excursions."),
bullet("Typical starting dose: 0.1 units of regular insulin per gram of dextrose in the TPN bag, adjusted daily based on glucose monitoring."),
blank(80),
subHead("Oral Agents in Cirrhosis -- Safety Profile"),
makeTable(
["Agent", "Use in Cirrhosis", "Rationale"],
[
["**Metformin**", "Contraindicated in Child C; use with caution in Child B", "Risk of lactic acidosis due to impaired hepatic lactate clearance; also risk of renal impairment triggering HRS"],
["**Sulphonylureas**", "Avoid in advanced CLD", "Prolonged hypoglycaemia risk (reduced hepatic metabolism); Child C is absolute contraindication"],
["**Thiazolidinediones** (pioglitazone)", "Generally avoid", "Fluid retention worsens ascites/oedema; avoid in decompensated disease"],
["**SGLT2 inhibitors**", "Avoid in decompensated CLD", "Risk of volume depletion precipitating HRS; UTI risk in immunocompromised; euglycaemic DKA (rare)"],
["**GLP-1 agonists**", "Limited data; may be considered in MAFLD-related cirrhosis (compensated)", "Emerging evidence in MASH; avoid in decompensated disease"],
["**Insulin**", "**Drug of choice** in advanced CLD", "No hepatic metabolism required; dose can be titrated precisely; safest in Child B/C"],
],
[2200, 1800, 4600]
),
blank(100),
correctionNote("The original listed 'euglycaemic DKA' as the primary concern with SGLT2i in cirrhosis. The more clinically relevant concerns are: (1) volume depletion potentially triggering HRS in a patient with marginal renal perfusion, and (2) infection risk (UTI/perineal infections) in an immunocompromised cirrhotic. Euglycaemic DKA is a real but rarer risk. The SGLT2i concern list should be ordered by clinical relevance."),
blank(80),
refLine("ADA Standards of Care in Diabetes 2024, Section 16; El-Azab G et al. PMID 42001361 (2026); Zhang J et al. Arch Med Sci 2025 (PMID 40395912); EASL CPG Decompensated Cirrhosis, J Hepatol 2018."),
blank(100),
];
}
// ══════════════════════════════════════════════════════════════════════════
// Q9
// ══════════════════════════════════════════════════════════════════════════
function q9() {
return [
...questionBlock(9, "Complete differential diagnosis of ascites (DDP framework). Why are PR and breast examinations mandatory in unexplained ascites?"),
answerHeader(),
blank(60),
subHead("DDP Framework for Ascites: SAAG-Based Classification"),
body("SAAG (Serum-Ascites Albumin Gradient) = Serum albumin - Ascites albumin. This single measurement distinguishes portal-hypertension-related causes (SAAG >=1.1 g/dL) from non-portal hypertension causes (SAAG <1.1 g/dL) with ~97% accuracy."),
blank(80),
makeTable(
["SAAG >=1.1 g/dL (Portal Hypertension)", "SAAG <1.1 g/dL (Non-Portal Hypertension)"],
[
["**Cirrhosis** (~80% of all ascites cases)", "**Peritoneal TB** (most important in Nepal/South Asia -- always exclude)"],
["Alcoholic hepatitis (with or without cirrhosis)", "**Peritoneal carcinomatosis** (ovarian, gastric, colorectal, breast, pancreatic, mesothelioma)"],
["**Cardiac ascites:** Right heart failure, constrictive pericarditis, tricuspid regurgitation -- ascites protein typically HIGH (>2.5 g/dL) despite high SAAG", "**Pancreatitis / Pancreatic ascites** (amylase-rich fluid; SAAG often <1.1)"],
["**Budd-Chiari Syndrome** -- high SAAG AND high protein (>2.5 g/dL) -- key distinguishing feature from cirrhosis", "**Nephrotic syndrome** -- low SAAG, low protein, massive peripheral oedema predominant"],
["Sinusoidal obstruction syndrome (SOS/VOD) -- post-HSCT or oxaliplatin", "**Serositis** (SLE, connective tissue disease) -- low SAAG; ANA, complement levels"],
["Massive hepatic metastases (replace sinusoids, elevate sinusoidal pressure)", "**Chylous ascites** -- lymphatic disruption; triglycerides >200 mg/dL in ascitic fluid; milky appearance"],
["Portal vein thrombosis on a background of cirrhosis", "Mesothelioma, primary peritoneal carcinoma"],
],
[4300, 4300]
),
blank(100),
subHead("Additional Diagnostic Tests on Ascitic Fluid"),
makeTable(
["Test", "Diagnoses", "Threshold"],
[
["SAAG", "Portal vs. non-portal HTN", ">=1.1 = portal HTN cause"],
["Total protein", "Cardiac ascites / BCS vs. cirrhosis; exudate/transudate", ">2.5 g/dL = cardiac, BCS, TB, malignancy"],
["Cell count + differential", "SBP (PMN >=250/mm3 = SBP)", "PMN >=250 = empiric antibiotics"],
["Cultures (blood culture bottles)", "SBP organisms", "Sensitivity improved with blood culture bottles"],
["Cytology (x3 samples)", "Malignant ascites", "50-60% sensitivity per sample; 3 samples increase yield"],
["ADA (Adenosine Deaminase)", "Peritoneal TB", ">36 IU/L suggests TB (sensitivity ~100%, specificity ~97% in low-HIV settings)"],
["Ascitic fluid amylase", "Pancreatic ascites", ">1000 U/L strongly suggests pancreatic cause"],
["Triglycerides", "Chylous ascites", ">200 mg/dL = chylous"],
["AFB smear + culture", "TB peritonitis", "Low sensitivity (~3%) but culture adds yield; PCR/Xpert MTB preferred"],
],
[2000, 3200, 3500]
),
blank(100),
subHead("Why PR and Breast Examination Are Mandatory in Unexplained Ascites"),
body("In any patient presenting with ascites where obvious CLD is absent, or where the SAAG is low, or where SAAG is borderline with no clear cirrhotic aetiology:"),
bullet("**Ovarian malignancy** is the most common malignant cause of ascites in women. Papillary serous adenocarcinoma of the ovary can produce massive ascites as its presenting feature (Meigs syndrome variant, pseudomyxoma peritonei). The CA-125 may be elevated; pelvic examination and transvaginal/transabdominal ultrasound are mandatory."),
bullet("**Rectal carcinoma** with peritoneal metastases is a common cause of carcinomatous ascites. Digital rectal examination can detect an anterior rectal mass, pelvic fullness, or blood on the glove."),
bullet("**Breast cancer** metastasises to the peritoneum and can present with ascites months to years after the primary diagnosis (or even before). Breast examination may reveal a previously undetected primary."),
bullet("**Krukenberg tumour:** Secondary ovarian tumour from gastric, colorectal, or breast primary -- pelvic examination may reveal bilateral ovarian masses."),
bullet("**Prostate cancer** (in men): DRE may reveal an irregular/hard prostate -- prostate carcinoma can metastasise to the peritoneum."),
blank(80),
body("The guiding principle: Ascites from peritoneal carcinomatosis may look clinically similar to cirrhotic ascites but has a fundamentally different management and prognosis. Every unexplained ascites demands a thorough search for occult malignancy -- and this requires examining body compartments that are routinely 'forgotten' in a busy ward setting."),
blank(80),
subHead("Workup for Malignant Ascites"),
bullet("Cytology x3 (peritoneal fluid) -- 50-60% per sample, up to 80-90% with 3 samples."),
bullet("Tumour markers: CA-125 (ovarian), CEA (colorectal, gastric), CA 19-9 (pancreatic, cholangiocarcinoma)."),
bullet("CT abdomen/pelvis with contrast (triple phase): Detects peritoneal deposits, omental cake, ovarian masses, primary tumour."),
bullet("PET-CT if primary is occult after above workup."),
bullet("Laparoscopy with peritoneal biopsy: Definitive diagnosis of TB peritonitis AND malignancy -- should be considered early in unexplained low-SAAG ascites."),
blank(80),
correctionNote("The original answer for Q9 was incomplete (cut off mid-sentence). This expanded answer completes the SAAG differential with all clinically relevant categories, adds the mandatory workup table for ascitic fluid analysis, and provides the full rationale for PR/breast examination including Krukenberg tumours, prostate cancer in men, and the principle of excluding occult malignancy in every case of unexplained ascites."),
blank(80),
refLine("Runyon BA. AASLD Practice Guidance: Management of Adult Patients with Ascites Due to Cirrhosis. Hepatology 2013 (updated 2021); Sleisenger & Fordtran 11e, Ch. on Ascites; Harrison's 22e (2025)."),
blank(100),
];
}
// ══════════════════════════════════════════════════════════════════════════
// FOOTER NOTE
// ══════════════════════════════════════════════════════════════════════════
function footerNote() {
return [
new Paragraph({ children: [new PageBreak()], spacing: { after: 0 } }),
blank(200),
new Paragraph({
children: [new TextRun({ text: "EDITORIAL NOTES ON IMPROVEMENTS MADE", font: "Arial", size: 26, bold: true, color: TEAL, allCaps: true })],
alignment: AlignmentType.CENTER,
spacing: { after: 200 },
}),
makeTable(
["Q", "Issue Found", "Correction Applied"],
[
["Q1", "5-year mortality stated as '50%' after first ascites", "Corrected to: 1-year mortality ~20% after first ascites; 5-year (post-decompensation) approaches 85% without transplant. D'Amico 4-stage model added with mortality data."],
["Q2", "BCAA indication phrased as 'protein-intolerant'", "Clarified: BCAA indicated when protein restriction needed due to refractory encephalopathy; NOT a routine supplement. 2026 meta-analysis (PMID 41285365) added."],
["Q3", "MPN proportion stated as '40-50%'; Nepal epidemiology missing", "Corrected to 'up to 41%' per textbook. Added critical Nepal-specific data: BCS = 17% of liver admissions in Kathmandu (Sleisenger & Fordtran, citing 1992 data). Highly relevant for this audience."],
["Q4", "No addition needed", "Expanded with clearer dry-weight estimation formula and ascites volume ranges. HGS bedside application emphasised."],
["Q5", "2018 EASL only referenced", "Updated to include AASLD 2023 guidance. MASLD/MASH terminology change noted. TM6SF2 genetic modifier added alongside PNPLA3."],
["Q6", "NAFLD used throughout; aetiological table lacked exam depth", "MAFLD/MASLD terminology update added. Wilson's 'K-F rings in hepatic-only' caveat added. Polycythaemia vera examination finding for BCS added."],
["Q7", "Good mechanistic answer; no significant errors", "Expanded with explicit comparison table. 'Exception' point added: PVT on cirrhosis background DOES produce ascites."],
["Q8", "SGLT2i risk prioritised incorrectly; hepatogenous DM section dated", "Reordered SGLT2i risks: volume depletion/HRS first, then infection, then euglycaemic DKA. 2026 precision medicine review (PMID 42001361) added."],
["Q9", "Incomplete -- cut off mid-sentence", "Full answer written: complete SAAG-based differential with all relevant causes, ascitic fluid analysis table, complete PR/breast exam rationale including Krukenberg tumour and prostate cancer in men, and malignant ascites workup."],
],
[400, 3000, 5300]
),
blank(200),
new Paragraph({
children: [new TextRun({ text: "Generated June 2026. Cross-referenced against: Harrison's 22e (2025), Sleisenger & Fordtran 11e, Yamada Gastroenterology 7e, Symptom to Diagnosis 4e, EASL/ESPEN/AASLD guidelines, and PubMed literature 2021-2026.", font: "Arial", size: 17, italics: true, color: MID_GRAY })],
alignment: AlignmentType.CENTER,
spacing: { after: 60 },
}),
];
}
// ══════════════════════════════════════════════════════════════════════════
// ASSEMBLE DOCUMENT
// ══════════════════════════════════════════════════════════════════════════
const doc = new Document({
numbering: NUMBERING,
styles: {
default: {
document: { run: { font: "Arial", size: 20, color: DARK } },
},
paragraphStyles: [
{
id: "Heading1", name: "Heading 1", basedOn: "Normal", next: "Normal", quickFormat: true,
run: { size: 36, bold: true, font: "Arial", color: TEAL },
paragraph: { spacing: { before: 360, after: 180 }, outlineLevel: 0 }
},
{
id: "Heading2", name: "Heading 2", basedOn: "Normal", next: "Normal", quickFormat: true,
run: { size: 28, bold: true, font: "Arial", color: TEAL },
paragraph: { spacing: { before: 200, after: 100 }, outlineLevel: 1 }
},
]
},
sections: [{
properties: {
page: {
size: { width: 12240, height: 15840 },
margin: { top: 1080, right: 1080, bottom: 1080, left: 1080 },
}
},
headers: {
default: new Header({
children: [
new Paragraph({
children: [
new TextRun({ text: "Faculty Q&A Bank: Decompensated CLD | PG Internal Medicine | June 2026", font: "Arial", size: 16, italics: true, color: MID_GRAY }),
],
alignment: AlignmentType.RIGHT,
border: { bottom: { style: BorderStyle.SINGLE, size: 4, color: TEAL } },
spacing: { after: 120 },
}),
],
}),
},
footers: {
default: new Footer({
children: [
new Paragraph({
children: [
new TextRun({ text: "Page ", font: "Arial", size: 16, color: MID_GRAY }),
new TextRun({ children: [PageNumber.CURRENT], font: "Arial", size: 16, color: MID_GRAY }),
new TextRun({ text: " of ", font: "Arial", size: 16, color: MID_GRAY }),
new TextRun({ children: [PageNumber.TOTAL_PAGES], font: "Arial", size: 16, color: MID_GRAY }),
],
alignment: AlignmentType.CENTER,
border: { top: { style: BorderStyle.SINGLE, size: 4, color: TEAL } },
spacing: { before: 120 },
}),
],
}),
},
children: [
...coverPage(),
...caseHeader(),
...q1(),
...q2(),
...q3(),
...q4(),
...q5(),
...q6(),
...q7(),
...q8(),
...q9(),
...footerNote(),
],
}],
});
Packer.toBuffer(doc).then(buffer => {
fs.writeFileSync("/home/daytona/workspace/cld-qa-bank/CLD_QA_Bank_Improved.docx", buffer);
console.log("SUCCESS: Document written.");
}).catch(err => {
console.error("ERROR:", err);
process.exit(1);
});
cd /home/daytona/workspace/cld-qa-bank && node generate_qa_bank.js 2>&1
python3 /home/daytona/skills/docx/scripts/office/validate.py /home/daytona/workspace/cld-qa-bank/CLD_QA_Bank_Improved.docx 2>&1
ls -lh /home/daytona/workspace/cld-qa-bank/CLD_QA_Bank_Improved.docx && python3 -c "import zipfile; z=zipfile.ZipFile('/home/daytona/workspace/cld-qa-bank/CLD_QA_Bank_Improved.docx'); print('ZIP valid. Files:', z.namelist()[:8])" 2>&1
pandoc /home/daytona/workspace/cld-qa-bank/CLD_QA_Bank_Improved.docx -t plain 2>&1 | head -80
CLD QA Bank Improved
Word Document · DOCX
Summary of All Improvements Made
Q1 - Ascites vs. UGI Bleed Prognosis
- 1-year mortality after first ascites: ~20%
- 5-year mortality after any decompensation (without transplant): approaches 85%
Q2 - Malnutrition
Q3 - Budd-Chiari Syndrome
Q4 - BMI in Oedematous Patients
Q5 - Alcohol Threshold for CLD
Q6 - Differential Diagnosis of CLD Aetiology
Q7 - PVT Causes Bleed Not Ascites
Q8 - Insulin Management in CLD
Q9 - Ascites Differential + PR/Breast Exam
- Complete SAAG-based differential with all clinically relevant categories (including cardiac ascites with its characteristic high-protein/high-SAAG pattern, and chylous ascites)
- Ascitic fluid analysis table (SAAG, total protein, cell count, ADA, amylase, triglycerides, AFB)
- Full rationale for PR/breast examination: ovarian carcinoma, rectal carcinoma, Krukenberg tumour, breast cancer peritoneal metastases, and prostate cancer in men
- Malignant ascites workup (cytology x3, CA-125/CEA/CA19-9, CT, PET, laparoscopy)